Cerebain’s Strategic Partner Adds Key Personnel to Accelerate Advancement of Device Development

COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech (OTCQB: CBBT) today announced that the company’s strategic partner, Sonos Models, Inc., has added key personnel to its staff to facilitate the acceleration in development of the company’s medical device. These additions come as Cerebain readies itself for clinical trials and the FDA application process in conjunction with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia.
 
About Cerebain Biotech Corp.
 
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
 
Forward-Looking Statements
 
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

 

Contacts

Cerebain Biotech Corp.
Mr. Alan Klitenic, 888-430-2221
info@cerebain.com

 
 

Source: Cerebain Biotech Corp.

Back to news